Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report

被引：1

作者：

Wang, Wen ^{[1
]}

Lu, Xu ^{[1
]}

Li, Chengbo ^{[1
]}

Teng, Wei ^{[1
]}

Cui, Wei ^{[1
]}

机构：

[1] China Med Univ, Affiliated Hosp 1, Dept Infect Dis, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China

来源：

BMC INFECTIOUS DISEASES | 2022年 / 22卷 / 01期

关键词：

Rhabdomyolysis; Rosuvastatin; Entecavir;

D O I：

10.1186/s12879-022-07254-0

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Rhabdomyolysis is a serious and potentially life threatening condition that can be caused by drugs. We report a case of acute hepatitis B with rhabdomyolysis after treatment with rosuvastatin and entecavir. Case presentation: A 72-year-old female was admitted to our hospital due to acute hepatitis B infection. She had taken atorvastatin for 3 months before being admitted to our hospital. After being administered entecavir (ETV) and rosuvastatin to replace atorvastatin, she suffered from muscle pain in both lower limbs and was diagnosed with rhabdomyolysis. After discontinuation of the two drugs, the patient's symptoms subsided and creatine kinase levels returned to normal. We hypothesize that the rhabdomyolysis was caused by the combination of rosuvastatin and ETV. Conclusions: We suggest that patients who use rosuvastatin and ETV be made aware of the complication of rhabdomyolysis.

引用

页数：3

共 5 条

[1] Benefit-risk assessment of rosuvastatin 10 to 40 milligrams [J].